Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Almirall SA    ALM   ES0157097017

ALMIRALL SA (ALM)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed BATS Europe - 12/18 05:30:00 pm
8.83 EUR   +4.99%
12/04 ALMIRALL : Phase IV ASCENT trial shows Tudorza reduces COPD exacerba..
11/06 ALMIRALL : Q3 results 2017
11/01ALMIRALL SA : quaterly earnings release
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Bolsa De Madrid
12/12/2017 12/13/2017 12/14/2017 12/15/2017 12/18/2017 Date
8.56(c) 8.39(c) 8.48(c) 8.41(c) 8.7 Last
860 741 416 233 429 951 295 466 512 012 Volume
+3.88% -1.99% +1.07% -0.83% +3.45% Change
More quotes
Financials (€)
Sales 2017 691 M
EBIT 2017 52,1 M
Net income 2017 -35,6 M
Finance 2017 58,8 M
Yield 2017 2,03%
Sales 2018 732 M
EBIT 2018 116 M
Net income 2018 91,1 M
Finance 2018 159 M
Yield 2018 1,84%
P/E ratio 2017 -
P/E ratio 2018 17,71
EV / Sales2017 2,02x
EV / Sales2018 1,77x
Capitalization 1 455 M
More Financials
Company
Almirall SA engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production.The company operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research... 
Sector
Pharmaceuticals
Calendar
02/26Earnings Release
More about the company
Surperformance© ratings of Almirall SA
Trading Rating : Investor Rating :
More Ratings
Latest news on ALMIRALL SA
12/06 ALMIRALL : Phase IV ASCENT Trial Shows Tudorza Reduces COPD Exacerbations And De..
12/04 ALMIRALL : Phase IV ASCENT trial shows Tudorza reduces COPD exacerbations and de..
11/06 ALMIRALL : Q3 results 2017
11/01ALMIRALL SA : quaterly earnings release
10/27 ALMIRALL : New randomized controlled study confirms the efficacy and tolerabilit..
09/07 ALMIRALL : Phase III AMPLIFY study shows Duaklir significantly improves lung fun..
08/28 ALMIRALL : appoints Peter Guenter as new CEO
08/22 ALMIRALL : announces Ron Menezes as new President & General Manager at Aqua Phar..
07/24 ALMIRALL'S H1 RESULTS 2017 : reiterating recent Guidance
07/19ALMIRALL SA : half-yearly earnings release
More news
Sector news : Pharmaceuticals - NEC
08:41aDJASTRAZENECA : Says Tagrisso Supplemental NDA Accepted by FDA
05:13aDJSANOFI : Philippines Probes Dengue Vaccination Drive That Went Ahead Despite War..
02:24aDJSANOFI : Philippines Probes Vaccination Drive Amid Red Flags
12/17 TEVA PHARMACEUTICAL INDUSTRIES : Strike over Teva Pharm job cuts briefly shuts d..
12/16 NELSON PELTZ : P&G appoints Peltz to board despite losing proxy battle
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/07 COBAS ASSET MANAGEMENT : Comments On Third Quarter 2017
11/06 Almirall SA 2017 Q3 - Results - Earnings Call Slides
11/06 Almirall SA 2017 Q3 - Results - Earnings Call Slides
07/11 Almirall SA (LBTSF) Updates Guidance for FY17 - Slideshow
03/21 AstraZeneca's Mistakes Mount
Chart ALMIRALL SA
Duration : Period :
Almirall SA Technical Analysis Chart | ALM | ES0157097017 | 4-Traders
Technical analysis trends ALMIRALL SA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 10,7 €
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
Peter Guenter Chief Executive Officer
Jorge Gallardo Ballart Chairman
David Nieto Chief Financial Officer
Eloi Crespo Cervera Vice President-Manufacturing & Technical Services
Bhushan D. Hardas Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALMIRALL SA-43.02%1 709
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386